Transparency notification received from Capital Grand Est SAS

Article 14 of the Law of 2 May 2007 on disclosure of major holdings

Mont-Saint-Guibert, Belgium, January 23, 2025, 21:00 – BIOSENIC (Euronext Brussels and Paris: BIOS) announces that it has received a transparency notification from Capital Grand Est SAS. The notifications details can be found below and can be consulted on the website of BioSenic, under the heading "*Major shareholders & transparency notices*".

The transparency notification indicates that the shareholdings held by **Capital Grand Est SAS** have crossed below the threshold of 5% as a result of the issuance of new shares of BioSenic on 12 December 2024.

The notification received from Capital Grand Est SAS dated 8 January 2024 contains the following information:

- Reason for the notification:
  - *Passive crossing of a threshold*
  - *Downward crossing of the minimum threshold*
- Notification by: *A person that notifies alone*
- Person subject to the notification requirement: *Capital Grand Est SAS*
- Transaction date: *12 December 2024*
- Threshold that is crossed: *5%*
- Denominator: *323 931 864*
- Full chain of controlled undertakings through which the holding is effectively held: *Capital Grand Est SAS is not under control*
- Additional information: *Capital Grand Est SAS is the management company that can execute the voting rights as it sees fit in the absence of specific instructions*

About BioSenic

BioSenic is a leading biotech company specializing in the development of clinical assets issued from its Medsenic's arsenic trioxide (ATO) platform. Key target indications for the autoimmune platform include graft-versus-host-disease (GvHD), systemic lupus erythematosus (SLE), and now systemic sclerosis (SSc).
Following the merger in October 2022, BioSenic combined the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger specifically enables Medsenic/Biosenic to develop an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO).

BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at http://www.biosenic.com.

About the main Medsenic/BioSenic technology platform

*The **ATO platform** provides derived active products with immunomodulatory properties and fundamental effects on the activated cells of the immune system. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT).*

*Medsenic has been successful in a phase 2 trial with its intravenous formulation, **Arscimed®**, which has orphan drug designation status by FDA and EMA. The company is heading towards an international phase 3 confirmatory study, with its new, IP-protected, OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE), using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin, mucosae, and the gastrointestinal tract). Systemic sclerosis is now full part of the clinical pipeline of Medsenic/BioSenic. This serious chronic disease badly affects skin, lungs, or vascularization, and has no current effective treatment. Preclinical studies on pertinent animal models are positive, giving good grounds to launch a phase 2 clinical protocol, using new immunomodulatory formulations of APIs recognized to be active on the immune system.*

The company is currently focusing its present R&D and clinical activities on a selective, accelerated development of its autoimmune platform.

For further information, please contact:

BioSenic SA
Finsys Management SRL, represented by its permanent representative Jean-Luc Vandebroek, managing director ad interim
investorrelations@biosenic.com